$3.55
-0.15 (-4.05%)
Open$3.69
Previous Close$3.70
Day High$3.73
Day Low$3.45
52W High$7.82
52W Low$3.02
Volume—
Avg Volume646.6K
Market Cap213.93M
P/E Ratio—
EPS$-1.35
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+560.3% upside
Current
$3.55
$3.55
Target
$23.44
$23.44
$15.10
$23.44 avg
$28.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 193.62M | 202.51M | 206.29M |
| Net Income | -27,587,371 | -28,749,471 | -33,771,699 |
| Profit Margin | -14.3% | -14.2% | -16.4% |
| EBITDA | -51,862,975 | -48,122,998 | -52,884,989 |
| Free Cash Flow | -39,587,712 | -47,283,878 | -36,549,207 |
| Rev Growth | +24.4% | +2.2% | +1.5% |
| Debt/Equity | 0.26 | 0.22 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |